The concurrent 424B5 and 8-K confirm this is a pure capital raise with no strategic catalyst. Monitor for shareholder vote on the additional warrants and any pipeline updates that could offset dilution. The stock may face continued pressure from the overhang of unregistered warrants.
Price Chart
Executive Summary
Lantern Pharma entered into a securities purchase agreement to sell approximately $4 million of common stock and pre-funded warrants at $1.09 per share, along with unregistered warrants exercisable at $1.09 per share (subject to shareholder approval). The offering closed on the same day as a 424B5 prospectus supplement filing, indicating the capital raise is financing general working capital needs. This is a dilutive equity offering for a clinical-stage biotech with no disclosed revenue, representing a material negative signal for existing shareholders.
Key Financial Metrics
Key Facts
- Lantern Pharma raised approximately $4 million via sale of 1,469,725 common shares and 2,200,000 pre-funded warrants at $1.09 per share.
- Investors also received unregistered warrants to purchase up to 3,669,725 shares at $1.09 per share, exercisable only after shareholder approval.
- The placement agent (Rodman & Renshaw) received a 7% cash fee and warrants for 5% of the offering shares at $1.3625 per share.
- Proceeds are for working capital purposes; no specific deal or partnership was announced alongside the raise.
- The offering was priced at the market close of $1.09 on September 28, 2026, with no premium.
- A 60-day lock-up on further equity issuance applies, but a 2-year ban on variable-rate transactions is in place.
Financial Impact
~$4 million gross proceeds (~$3.72 million net) raised at market price; immediate dilution of ~3.7 million shares (common + pre-funded warrants) on a base of ~13.5 million shares outstanding, representing ~27% dilution. Additional 3.67 million warrant shares (subject to shareholder approval) could add another ~27% dilution if exercised.
Risk Factors
- Immediate dilution of ~27% from the offering shares and pre-funded warrants.
- Potential additional dilution of ~27% if shareholder approval is obtained for the unregistered warrants.
- No disclosed revenue or near-term catalyst to absorb the dilution; clinical-stage biotech with high cash burn.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045100 |
| Exhibit: ex4-1.htm | 0001493152-26-045100 |
| Exhibit: ex4-3.htm | 0001493152-26-045100 |
| Exhibit: ex4-2.htm | 0001493152-26-045100 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6205 (+5.47%) |
Oct 13, 2026 14d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6205 (−12.69%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6205 (+27.86%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6205 (+37.95%) |
Sep 30, 2026 27d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6205 (+38.56%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6205 (−48.72%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6205 (−55.36%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6205 (−76.58%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6205 (+84.01%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6205 (−79.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers